Gut roundtable meeting paper: Selected recent advances in hepatocellular carcinoma

Alexander Gerbes*, Fabien Zoulim, Herbert Tilg, Jean François Dufour, Jordi Bruix, Valérie Paradis, Riad Salem, Markus Peck-Radosavljevic, Peter R. Galle, Tim F. Greten, Jean Charles Nault, Matias A. Avila

*Corresponding author for this work

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) ranks number three among the most frequent causes of death from solid tumors worldwide. With obesity and fatty liver diseases as risk factors on the rise, HCC represents an ever increasing challenge. While there is still no curative treatment for most patients numerous novel drugs have been proposed, but most ultimately failed in phase III trials. This manuscript targets therapeutic advances and most burning issues. Expert key point summaries and urgent research agenda are provided regarding risk factors, including microbiota, need for prognostic and predictive biomarkers and the equivocal role of liver biopsy. Therapeutic topics highlighted are locoregional techniques, combination therapies and the potential of immunotherapy. Finally the manuscript provides a critical evaluation of novel targets and strategies for personalized treatment of HCC.

Original languageEnglish (US)
Pages (from-to)380-388
Number of pages9
JournalGut
Volume67
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Hepatocellular Carcinoma
Therapeutics
Manuscripts
Microbiota
Fatty Liver
Immunotherapy
Liver Diseases
Cause of Death
Obesity
Biomarkers
Biopsy
Liver
Research
Pharmaceutical Preparations
Neoplasms

Keywords

  • clinical trials
  • hepatocellular carcinoma

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Gerbes, A., Zoulim, F., Tilg, H., Dufour, J. F., Bruix, J., Paradis, V., ... Avila, M. A. (2018). Gut roundtable meeting paper: Selected recent advances in hepatocellular carcinoma. Gut, 67(2), 380-388. https://doi.org/10.1136/gutjnl-2017-315068
Gerbes, Alexander ; Zoulim, Fabien ; Tilg, Herbert ; Dufour, Jean François ; Bruix, Jordi ; Paradis, Valérie ; Salem, Riad ; Peck-Radosavljevic, Markus ; Galle, Peter R. ; Greten, Tim F. ; Nault, Jean Charles ; Avila, Matias A. / Gut roundtable meeting paper : Selected recent advances in hepatocellular carcinoma. In: Gut. 2018 ; Vol. 67, No. 2. pp. 380-388.
@article{442d9fbca55043babd3943efb9c16708,
title = "Gut roundtable meeting paper: Selected recent advances in hepatocellular carcinoma",
abstract = "Hepatocellular carcinoma (HCC) ranks number three among the most frequent causes of death from solid tumors worldwide. With obesity and fatty liver diseases as risk factors on the rise, HCC represents an ever increasing challenge. While there is still no curative treatment for most patients numerous novel drugs have been proposed, but most ultimately failed in phase III trials. This manuscript targets therapeutic advances and most burning issues. Expert key point summaries and urgent research agenda are provided regarding risk factors, including microbiota, need for prognostic and predictive biomarkers and the equivocal role of liver biopsy. Therapeutic topics highlighted are locoregional techniques, combination therapies and the potential of immunotherapy. Finally the manuscript provides a critical evaluation of novel targets and strategies for personalized treatment of HCC.",
keywords = "clinical trials, hepatocellular carcinoma",
author = "Alexander Gerbes and Fabien Zoulim and Herbert Tilg and Dufour, {Jean Fran{\cc}ois} and Jordi Bruix and Val{\'e}rie Paradis and Riad Salem and Markus Peck-Radosavljevic and Galle, {Peter R.} and Greten, {Tim F.} and Nault, {Jean Charles} and Avila, {Matias A.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1136/gutjnl-2017-315068",
language = "English (US)",
volume = "67",
pages = "380--388",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "2",

}

Gerbes, A, Zoulim, F, Tilg, H, Dufour, JF, Bruix, J, Paradis, V, Salem, R, Peck-Radosavljevic, M, Galle, PR, Greten, TF, Nault, JC & Avila, MA 2018, 'Gut roundtable meeting paper: Selected recent advances in hepatocellular carcinoma', Gut, vol. 67, no. 2, pp. 380-388. https://doi.org/10.1136/gutjnl-2017-315068

Gut roundtable meeting paper : Selected recent advances in hepatocellular carcinoma. / Gerbes, Alexander; Zoulim, Fabien; Tilg, Herbert; Dufour, Jean François; Bruix, Jordi; Paradis, Valérie; Salem, Riad; Peck-Radosavljevic, Markus; Galle, Peter R.; Greten, Tim F.; Nault, Jean Charles; Avila, Matias A.

In: Gut, Vol. 67, No. 2, 01.02.2018, p. 380-388.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Gut roundtable meeting paper

T2 - Selected recent advances in hepatocellular carcinoma

AU - Gerbes, Alexander

AU - Zoulim, Fabien

AU - Tilg, Herbert

AU - Dufour, Jean François

AU - Bruix, Jordi

AU - Paradis, Valérie

AU - Salem, Riad

AU - Peck-Radosavljevic, Markus

AU - Galle, Peter R.

AU - Greten, Tim F.

AU - Nault, Jean Charles

AU - Avila, Matias A.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Hepatocellular carcinoma (HCC) ranks number three among the most frequent causes of death from solid tumors worldwide. With obesity and fatty liver diseases as risk factors on the rise, HCC represents an ever increasing challenge. While there is still no curative treatment for most patients numerous novel drugs have been proposed, but most ultimately failed in phase III trials. This manuscript targets therapeutic advances and most burning issues. Expert key point summaries and urgent research agenda are provided regarding risk factors, including microbiota, need for prognostic and predictive biomarkers and the equivocal role of liver biopsy. Therapeutic topics highlighted are locoregional techniques, combination therapies and the potential of immunotherapy. Finally the manuscript provides a critical evaluation of novel targets and strategies for personalized treatment of HCC.

AB - Hepatocellular carcinoma (HCC) ranks number three among the most frequent causes of death from solid tumors worldwide. With obesity and fatty liver diseases as risk factors on the rise, HCC represents an ever increasing challenge. While there is still no curative treatment for most patients numerous novel drugs have been proposed, but most ultimately failed in phase III trials. This manuscript targets therapeutic advances and most burning issues. Expert key point summaries and urgent research agenda are provided regarding risk factors, including microbiota, need for prognostic and predictive biomarkers and the equivocal role of liver biopsy. Therapeutic topics highlighted are locoregional techniques, combination therapies and the potential of immunotherapy. Finally the manuscript provides a critical evaluation of novel targets and strategies for personalized treatment of HCC.

KW - clinical trials

KW - hepatocellular carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85042603956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042603956&partnerID=8YFLogxK

U2 - 10.1136/gutjnl-2017-315068

DO - 10.1136/gutjnl-2017-315068

M3 - Article

C2 - 29150490

AN - SCOPUS:85042603956

VL - 67

SP - 380

EP - 388

JO - Gut

JF - Gut

SN - 0017-5749

IS - 2

ER -

Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V et al. Gut roundtable meeting paper: Selected recent advances in hepatocellular carcinoma. Gut. 2018 Feb 1;67(2):380-388. https://doi.org/10.1136/gutjnl-2017-315068